$1.4 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 67.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF SPYput | $206,430,000 | +0.4% | 1,000,000 | 0.0% | 14.74% | +7.9% | |
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDadr | $102,795,000 | +2.1% | 1,650,000 | -5.7% | 7.34% | +9.7% |
| MASI | Sell | MASIMO CORP | $89,046,000 | +18.6% | 2,700,000 | -5.3% | 6.36% | +27.4% |
| MDCO | Buy | MEDICINES CO | $70,050,000 | +91.8% | 2,500,000 | +89.4% | 5.00% | +106.0% |
| GHDX | Sell | GENOMIC HEALTH INC | $64,155,000 | -6.7% | 2,100,000 | -2.3% | 4.58% | +0.2% |
| ESRX | EXPRESS SCRIPTS HLDG CO | $60,739,000 | +2.5% | 700,000 | 0.0% | 4.34% | +10.0% | |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $57,680,000 | +11.9% | 7,000,000 | -6.7% | 4.12% | +20.2% |
| UAM | Buy | UNIVERSAL AMERN CORP NEW | $55,909,000 | +31.9% | 5,234,898 | +14.6% | 3.99% | +41.6% |
| AMAG | Buy | AMAG PHARACEUTICALS INC | $55,657,000 | +30.6% | 1,018,246 | +1.8% | 3.97% | +40.2% |
| OFIX | Buy | ORTHOFIX INTL N V | $53,835,000 | +43.3% | 1,500,000 | +20.0% | 3.84% | +53.9% |
| LH | Sell | LABORATORY CORP AMER HLDGS | $50,436,000 | -6.5% | 400,000 | -20.0% | 3.60% | +0.4% |
| CYBX | New | CYBERONICS INC | $48,690,000 | – | 750,000 | +100.0% | 3.48% | – |
| SEM | New | SELECT MED HLDINGS CORP | $44,490,000 | – | 3,000,000 | +100.0% | 3.18% | – |
| ABBV | New | ABBVIE INC | $43,905,000 | – | 750,000 | +100.0% | 3.14% | – |
| KERX | KERYX BIOPHARMACEUTICALS INC | $38,190,000 | -10.0% | 3,000,000 | 0.0% | 2.73% | -3.4% | |
| BRKR | BRUKER CORP | $36,940,000 | -5.9% | 2,000,000 | 0.0% | 2.64% | +1.1% | |
| KND | KINDRED HEALTHCARE INC | $35,685,000 | +30.9% | 1,500,000 | 0.0% | 2.55% | +40.5% | |
| SQNM | Buy | SEQUENOM INC | $35,550,000 | +9.8% | 9,000,000 | +2.9% | 2.54% | +17.9% |
| CNMD | Sell | CONMED CORP | $33,876,000 | -45.6% | 670,943 | -51.6% | 2.42% | -41.6% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $32,775,000 | – | 7,500,000 | +100.0% | 2.34% | – |
| AMRN | AMARIN CORP PLCspons adr new | $28,080,000 | +138.9% | 12,000,000 | 0.0% | 2.00% | +156.4% | |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $19,245,000 | -19.1% | 1,482,662 | -15.2% | 1.37% | -13.1% |
| TRVN | TREVENA INC | $18,712,000 | +9.0% | 2,870,000 | 0.0% | 1.34% | +17.1% | |
| CCRN | CROSS CTRY HEALTHCARE INC | $16,872,000 | -5.0% | 1,422,565 | 0.0% | 1.20% | +2.1% | |
| EPRSQ | New | EPIRUS PHARMACEUTICALS IN | $16,535,000 | – | 1,847,500 | +100.0% | 1.18% | – |
| BIOS | New | BIOSCRIP INC | $13,290,000 | – | 3,000,000 | +100.0% | 0.95% | – |
| ANGO | Buy | ANGIODYNAMICS INC | $12,960,000 | +87.0% | 728,483 | +99.8% | 0.92% | +100.7% |
| MDRX | New | ALLSCRIPTS HEALTHCASE SOLUTN | $11,960,000 | – | 1,000,000 | +100.0% | 0.85% | – |
| BIOL | Buy | BIOLASE INCwarrant | $11,283,000 | -22.7% | 7,388,867 | +33.2% | 0.81% | -16.9% |
| PLX | New | PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $6,904,000 | – | 9,000,000 | +100.0% | 0.49% | – |
| NVTA | New | INVITAE CORP | $6,704,000 | – | 400,000 | +100.0% | 0.48% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $5,652,000 | – | 864,223 | +100.0% | 0.40% | – |
| CRDC | CARDICA INC | $5,274,000 | -10.0% | 8,374,846 | 0.0% | 0.38% | -3.3% | |
| TRGT | TARGACEPT INC | $4,633,000 | +12.9% | 1,560,000 | 0.0% | 0.33% | +21.2% | |
| New | PROTALIX BIOTHEAPEUTICS INC | $3,560,000 | – | 2,000,000 | +100.0% | 0.25% | – | |
| INO | INOVIO PHARMACEUTICALS INC | $2,040,000 | -11.1% | 250,000 | 0.0% | 0.15% | -4.6% | |
| BIOL | Exit | BIOLASE INCcall | $0 | – | -1,841,173 | -100.0% | -0.01% | – |
| BRLI | Exit | BIO-REFERENCE LABS INC | $0 | – | -11,485 | -100.0% | -0.02% | – |
| EGRX | Exit | EAGLE PHARMACEUTICAL INC | $0 | – | -200,400 | -100.0% | -0.21% | – |
| PLX | Exit | PROTALIX BIOTHERAPEUTICS INC | $0 | – | -2,000,000 | -100.0% | -0.24% | – |
| Exit | PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $0 | – | -9,000,000 | -100.0% | -0.46% | – | |
| AFFX | Exit | AFFYMETRIX INC | $0 | – | -1,000,000 | -100.0% | -0.66% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -2,000,000 | -100.0% | -0.79% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -197,622 | -100.0% | -0.88% | – |
| ALR | Exit | ALERE INC | $0 | – | -500,000 | -100.0% | -1.26% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -525,000 | -100.0% | -1.81% | – |
| WW | Exit | WEIGHT WATCHERS INTL INC NEW | $0 | – | -1,146,741 | -100.0% | -1.89% | – |
| TEVA | Exit | TEVA PHARMACEUTICALS INDS LTDcall | $0 | – | -500,000 | -100.0% | -1.91% | – |
| PFNX | Exit | PFIZER INCcall | $0 | – | -1,000,000 | -100.0% | -2.07% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -2,500,000 | -100.0% | -2.20% | – |
| MYL | Exit | MYLAN INC | $0 | – | -750,000 | -100.0% | -2.81% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCcall | $0 | – | -1,000,000 | -100.0% | -2.84% | – |
| 5100PS | Exit | VOLCANO CORPORATION | $0 | – | -2,550,000 | -100.0% | -3.03% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -1,750,000 | -100.0% | -4.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.